Elvitegravir "Quad" Single-tablet Regimen Shows Continued HIV Suppression at 48 Weeks

HIVandHepatitis.com: "SUMMARY: Gilead Science's experimental 'Quad' pill -- a once-daily single-tablet coformulation containing the new integrase inhibitor elvitegravir, the novel boosting agent cobicistat (GS 9350), and tenofovir plus emtricitabine (the drugs in the Truvada pill) -- continued to demonstrate potent antiviral activity and good tolerability at 48 weeks, according to data presented this week at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010). In a second comparison, cobicistat worked as well as ritonavir as a booster for atazanavir, with similar changes in kidney function."